Protein A Resin Market (2026 - 2033)

Protein A Resin Market Summary

The global protein A resin market size was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 2.9 billion in 2033, at a CAGR of 7.4% from 2026 to 2033. North America dominated the market, accounting for more than 41.0% of the market share. Protein A resins are used for the purification and fragmentation of immunoglobulins from biological fluids & cell culture media, and for the immunoprecipitation of proteins and antigens.

The major application of the protein A resin is monoclonal antibody production. Furthermore, the global industry is expanding due to increased drug development by the biotechnology & biopharmaceutical industries, growing research on monoclonal antibodies, and increased expenditure in synthetic biology. Moreover, there is an increase in demand for protein-engineered products used in vaccine and therapeutic development by the biopharmaceutical industry, which has a positive impact on the global industry and is one of the major driving factors.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Strong uptake of monoclonal antibody therapeutics, rapid biosimilar commercialization, and wider use of bioprocessing equipment are driving this growth. Large antibody manufacturers are increasing their capture chromatography capacity as they produce antibodies, which means they need to buy more high-capacity agarose and new fiber matrices. For instance, in June 2025, Cytiva completed major expansion projects across the U.S., Europe, and Asia as part of a USD 1.6 billion investment plan running through 2028 to enhance biopharmaceutical manufacturing capacity. The company has doubled chromatography resins production capacity in Uppsala, Sweden, and is establishing new manufacturing sites in Michigan and expanding filtration capabilities across multiple locations. This benefits suppliers, with biopharma firms now sourcing from multiple suppliers to reduce risk, creating new opportunities for local resin producers.

New high-throughput fiber-based adsorbents that work quickly are attracting process development teams seeking to boost productivity. The competition is moderate: top vendors keep their market share with recombinant-ligand technologies and global regulatory support, but polymer and fiber competitors are closing in on their performance.

Analyst Perspective

The protein A resin market is experiencing steady growth, driven by increasing demand for monoclonal antibodies and rising incidences of chronic diseases.  Biopharmaceutical companies largely use protein A resin in mAb purification and chromatography due to its high purification capacity and overall manufacturing efficiency. The expanding popularity of personalized medicine and continuous bioprocessing is further supporting market growth. As demand for high-capacity downstream processing solutions continues to rise, companies that focus on product innovation, such as alkali-resistant, cost-efficiency, and application diversification, will be well-positioned to capitalize on long-term growth opportunities.

Type Insights

The recombinant protein A resin segment dominated the industry in 2025 and accounted for the largest share of more than 58.0% of the overall revenue. It is used to increase the solubility and improve the sensitivity of alkaline solutions. The recombinant protein A resin ligand is coupled to agarose to provide high binding capacity for immunoglobulin during immunoglobulin fragmentation. It has a more specific binding capacity. Therefore, the growing demand for recombinant protein resins in the pharmaceutical industry, driven by technological advances in the drug discovery process, will drive segment growth over the forecast years.

In June 2025, Ecolab Life Sciences, launched Purolite AP+50 resin to help achieve cost savings and optimize operations throughout the antibody manufacturing process. Purolite AP+50 is an affinity chromatography resin with a 50-micron bead size offering the highest dynamic binding capacity of the AP resin platform while providing excellent durability for monoclonal antibody capture. On the other hand, natural protein A is the fastest-growing segment and is expected to further drive demand. It is obtained from Staphylococcus aureus and is derived from the bacterial cells of this species used for the purification of mAbs. In addition, natural protein A resins have a wide range of applications in biomedical research for antibody purification, affinity chromatography, and vaccine and therapeutics production. Moreover, the segment is estimated to register the fastest growth from 2026 to 2033 due to its ability to minimize ligand leaching and stability issues associated with traditional protein A resins.

Product Insights

The agarose-based protein A segment dominated the industry in 2025 and accounted for the maximum share of more than 42.0% of the overall revenue. This is attributed to the high binding specificity of ligands to proteins compared with other matrices. In addition, agarose-based protein A resins offer greater longevity, improved mechanical strength, and a high capacity for metal dopant absorption at a suitable pH. This trend will continue to drive segment growth over the forecast period. For instance, in May 2025, DuPont expanded its bioprocessing portfolio with the launch of the DuPont AmberChrom TQ1 chromatography resin for the purification of oligonucleotides and peptides, supporting a wide range of biopharma applications. The new agarose-based chromatography resin offers increased loading capacity, higher throughput, and lower pressure requirements than comparable products in the same class.

The organic polymer-based protein A segment is estimated to register the fastest growth rate during the projected period. This is attributable to its fast, large-molecule separation properties. They also have high biocompatibility and biodegradability, including a wide range of applications in imaging, biosensors, drug delivery, and bioseparation. Moreover, organic polymer-based protein A matrix resins exhibit high solubility, safety, and stability when used with nanoparticles and can be used for targeted drug delivery by many biopharmaceutical and biotechnological research institutes. Thus, propelling the segment growth.

Application Insights

The antibody purification segment held the largest revenue share of approximately 56.0% in 2025. There has been a constant demand for mAbs for therapeutic production, research, and industrial purposes. Antibody purification includes the isolation and enrichment of antibodies from polyclonal Abs, ascites fluid, and mAb cell culture supernatants. This has driven the demand for commercial protein A resins production for the various downstream processes of antibody production. For instance, in June 2024, Ecolab announced that its Purolite resin business, together with Repligen Corporation, has commercially launched Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes. This latest innovation is designed for large-scale commercial manufacturing of monoclonal antibodies, where cost of goods is critical for biologic drug developers. The increasing burden of chronic diseases has led to more demand for monoclonal antibodies for the treatment and cure of disease. Moreover, increasing awareness of the treatment of the aforementioned disease among both the general public and healthcare professionals also drives the market.

The immunoprecipitation application segment is estimated to register the fastest CAGR from 2026 to 2033. This is due to the application of immunoprecipitation in the R&D sector, which is flourishing in the biopharmaceutical and biotechnology industries. The segment will acquire a significant share and dominate the industry in the coming years.

End User Insights

The pharmaceutical & biopharmaceutical companies segment accounted for the highest share at approximately 59.0% in 2025. The increasing adoption of protein A resins in drug discovery, mAb, vaccine, and therapeutic production processes in biopharmaceutical manufacturing, as well as the rising use of continuous manufacturing processes, accounts for a large share of this segment. The rising demand for protein engineering, driven by technological advancements and new scientific advances, fuels the segment's growth. Technological advancements in the pharmaceutical and biotechnology sectors, as well as the rapid global growth of the biopharmaceutical sector, are expected to drive this segment’s revenue growth over the forecast period.

The government & academic institutions segment is expected to expand at a lucrative CAGR from 2026 to 2033. This is due to a rise in global healthcare expenditure and government funding for R&D, and to the increasing role of therapeutics, mAbs, and techniques for disease surveillance and outbreak prevention. In November 2025, Ginkgo Bioworks secured a contract worth up to USD 22.2 million through the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) for protection against filoviruses such as Ebola (EBOV) and Sudan (SUDV). Similarly, growth in hospital testing capacities post-pandemic and the availability of high-throughput testing capabilities can considerably boost the market prospects for the protein A resins market.

Regional Insights

North America dominated the industry in 2025 and accounted for the highest share of more than 41.0% of the overall revenue. This is due to the increasing demand for protein-based therapeutics to treat infectious diseases and the growing number of FDA-approved pharmaceutical and biotechnology companies in this region. Moreover, an increase in collaborations, mergers, and acquisitions among key players is propelling the industry's growth. For instance, in April 2026, Merck, a leading science and technology company, announced it had successfully closed the acquisition of JSR Life Sciences' chromatography business. The acquisition adds Amsphere Protein A resins and advanced Protein A chromatography capabilities to Merck’s downstream processing portfolio, enabling efficient, scalable purification of monoclonal antibodies. Furthermore, the government and private entities are also engaged in increasing R&D and healthcare development.

To learn more about this report, Download Free Sample Report

Rapid, ongoing improvements in healthcare & R&D infrastructure, along with rising economic assistance from governments in the region, can all be attributed to regional market growth. Moreover, life science research activities in this region mainly focus on using resins in drug discovery, thereby propelling the market. Along with this, the increasing geriatric population, leading to a rise in the health issues such as cancer and arthritis, will also support the region’s growth.

Asia Pacific Protein A Resin Market Trends

Asia Pacific is expected to record the highest CAGR during the forecast period due to increasing healthcare investments, supportive government policies, and increasing demand for biologic drugs. Countries including China, South Korea, Japan and Singapore are becoming places for biotech companies. Many global pharmaceutical companies are moving to these countries. The need for high-quality purification technologies such as protein A resin is growing as more local and international companies set up manufacturing and R&D facilities in the region. For instance, in July 2025, Shimadzu announced its collaboration with Sepragen Corporation: the expansion of the strategic partnership to include India. With the inclusion of India, Shimadzu further strengthens its dedication to supporting the rapidly expanding biopharmaceutical sector, particularly in the areas of human plasma fractionation and recombinant products such as insulin and its analogs, mAbs and ADCs, vaccines and gene therapy drug manufacturing. In addition, cost-effective production capabilities and a large patient population are encouraging biologics development, further increasing the demand for protein A resins across Asia Pacific.

Key Protein A Resin Market Companies Insights

Key players are implementing various strategies, including partnerships through mergers and acquisitions, geographical expansion, and strategic collaborations, to expand their industry presence.

Key Protein A Resin Companies

The following key companies have been profiled for this study on the protein A resin market.

• GE Healthcare

• Merck Millipore

• PerkinElmer, Inc.

• GenScript Biotech Corp.

• Agilent Technologies

• Repligen Corp.

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories, Inc.

• Abcam PLC.

• Novasep Holdings SAS

Recent Developments

• In August 2025, Bio-Works Technologies AB announced the launch of WorkBeads affimAb Edge, a new premium resin for the purification of monoclonal antibodies (mAbs). The product is designed to meet the high demands of the rapidly growing biopharmaceutical industry and strengthens Bio-Works’ position in the key segment of affinity chromatography.

• In September 2024, JSR Life Sciences, a JSR Group company, announced the launch of its next-generation protein A chromatography resin, Amsphere A+. Amsphere™ A+ uses a proprietary protein ligand and advanced polymer technology to significantly outperform its predecessor, Amsphere A3, in terms of binding capacity, alkali stability and pressure-flow property, resulting in improved efficiency of the production process.

Global Protein A Resin Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global protein A resin market report based on type, product, application, end-user, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Natural Protein A

  • Recombinant Protein A

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Agarose-based Protein A

  • Glass/Silica-based Protein A

  • Organic Polymer-based Protein A

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Antibody Purification

  • Immunoprecipitation

• End-users Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biopharmaceutical Companies

  • Academic Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait